GSK: RSV vaccine Arexvy approved in Europe

(CercleFinance.com) - GSK announced on Wednesday that the European Commission had approved the marketing of Arexvy, its vaccine against respiratory syncytial virus (RSV) in adults aged 60 and over.


The British laboratory says that this is the first time that a vaccine against RSV in adults has been approved by Brussels, enabling it to market the product in 30 European countries.

Every year, RSV - a highly contagious respiratory virus - causes over 270,000 hospitalisations and around 20,000 deaths in adults aged 60 and over in Europe.

In April, Arexvy received a positive recommendation from the CHMP of the EMA, based on Phase III clinical results showing an efficacy rate of 82.6%, including 94.6% in the most frail patients.


Copyright (c) 2023 CercleFinance.com. All rights reserved.